


## Raltegravir-<sup>13</sup>C,<sub>3</sub>d<sub>3</sub> potassium

<b>Cat. No.:</b>	HY-10353AS1
<b>Molecular Formula:</b>	C <sub>19</sub> <sup>13</sup> CH <sub>17</sub> D <sub>3</sub> FKN <sub>6</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	486.52
<b>Target:</b>	HIV; HIV Integrase; Isotope-Labeled Compounds
<b>Pathway:</b>	Anti-infection; Metabolic Enzyme/Protease; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Raltegravir- <sup>13</sup> C, <sub>3</sub> d <sub>3</sub> potassium is <sup>13</sup> C labeled Raltegravir potassium (HY-10353A). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
<b>In Vitro</b>	<p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.</p> <p>PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC<sub>50</sub> of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC<sub>50</sub> of 200 nM, indicating a approx twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme<sup>[2]</sup>.</p> <p>Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC<sub>95</sub> of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity<sup>[3]</sup>.</p> <p>Raltegravir cellular permeability is reduced in the presence of magnesium and calcium<sup>[4]</sup>. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) efficiently block viral replication<sup>[5]</sup>. In acutely infected human lymphoid CD4<sup>+</sup> T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC<sub>90</sub> in the low nanomolar range<sup>[6]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy<sup>[6]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

### REFERENCES

- [1]. Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62.
- [2]. Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6
- [3]. Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9

---

[4]. Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). *Mol Pharmacol*. 2011 Oct;80(4):565-72.

[5]. Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. *Retrovirology*, 2010. 7: p. 21.

[6]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA